SynthesisClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025
Safety and Tolerability of Pivmecillinam During More Than Four Decades of Clinical Experience: A Systematic Review.
Synthesis in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07407673 (Prediction and Prevention of Bloodstream Infections After Kidney Transplantation - The PREDICT Study), which is not on this map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prediction and Prevention of Bloodstream Infections After Kidney Transplantation - The PREDICT Study
Who cites it
6 citing papers in PubMed.
- Variation in Guidelines for the Management of Acute Uncomplicated Urinary Tract Infections Across the United States, Europe, and Australia.International urogynecology journal · 2026Review
- Pivmecillinam for Treatment of Uncomplicated Urinary Tract Infection: New Efficacy Analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Pivmecillinam for Treatment of Uncomplicated Urinary Tract Infections: The Full Picture Combines Extensive Clinical Experience and Emerging Data.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Similarities in the consumption trajectory of antibacterial drugs in the outpatient care sector in Germany from 1986 to 2022: identification of shared patterns, correlation analysis of prescribed defined daily dose and assessment of underlying influences.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Optimizing Prevention of Recurrent Urinary Tract Infections in Older Patients with Frailty.Drugs & aging · 2025Review
- Sonosynthesis of new functionalized optically active triazinesRSC advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The recent US Food and Drug Administration approval of pivmecillinam-an oral prodrug of the amidinopenicillin antibiotic mecillinam-presents a valuable opportunity to address the need for new treatments for uncomplicated urinary tract infection (uUTI). We report findings of a systematic literature review of the safety profile of pivmecillinam/mecillinam based on more than 40 years' experience, mainly in Europe and Canada, to describe its tolerability profile and identify any important safety signals. In total, 110 eligible publications were identified describing use of pivmecillinam/mecillinam as monotherapy or in combination, for treatment of uUTI or other infectious conditions. These studies revealed a benign safety and tolerability profile, awareness of which will inform treatment decisions as pivmecillinam is made available in the United States. Together with the evidence for efficacy of, and minimal resistance to, pivmecillinam, the findings of this review support the position of pivmecillinam as a first-line treatment for uUTI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.